Tokyo, Nov 20, 2014 - (ACN Newswire) - JCI Pharmaceutical Co., Ltd. has announced approval by the US FDA for its MN colloid iodine (C.I.M.N), a formulation utilizing a world-first technology for converting iodine into a colloidal state to make it absorbable into the body at a large doses. The new formulation converts iodine[1] into a colloid state[2] and further processes it to make it ingestible into the human body in large doses.
JCI obtained FDA approval for three formulations - ointment, internal medicine, and eye drops - to be sold over the counter (OTC) in the United States. The internal medicine is chiefly effective in the treatment of various cancer types including terminal cancer. The ointment is effective in the treatment of general cutaneous diseases including atopic dermatitis, and external cutaneous lesions. The eye drop is effective in the treatment of various infectious diseases and the general ophthalmologic diseases including myodesopsia.
C.I.M.N receives approval from US FDA are converted iodine allows large-dose ingestion into the body which activates the metabolic function, improves immunity, and has a high efficacy of enhancing the natural healing power.
The internal medicine is effective in terminal cancer cases including prostate carcinoma, gastric cancer, scirrhous gastric cancer, sigmoid colon cancer, uterine cancer, esophageal cancer, colon cancer, pancreatic cancer, and lung cancer, and also has produced complete remission of malignant lymphoma and leukemia.
Concomitant use of the internal medicine with the injection or intravenous fluid is more effective for severe cancer, and with the inhalant for respiratory diseases including lung cancer. (The internal medicine has been approved and the FDA applications for the injection, intravenous fluid, and inhalant are pending).
While C.I.M.N is effective in monotherapy, it also exerts high efficacy in concomitant therapy with conventional cancer therapies including anticancer agents and radiotherapy.
Fumiaki Aoshima, CEO of JCI Pharmaceutical Co., Led. explained that FDA approval was crucial, as "we considered approval for marketing medicines (OTC) in the United States, where nearly a half of the worldwide medicines are produced, as the best way for proving the safety and reliability of the formulation for the global market, and effectively spreading the product worldwide."
He also stated, "Our colloidal iodine has already exerted a significant therapeutic effect against intractable diseases including terminal cancer in Japan. We wish to contribute to international medical care in future by supplying our colloidal iodine products to people suffering from diseases around the world."
Dr. Kazuhiro Maeyama, chief director of the Colloidal Iodine Therapy Society and chief director of Mediart Clinic, which is engaged in the treatment of terminal cancer patients using the colloidal iodine products of JCI Pharmaceuticals, stated, "In my experience of more than 10 years of using colloidal iodine, I found many clinical cases where colloidal iodine exerted therapeutic effects in concomitant use with conventional cancer therapies as well as its therapeutic effects in monotherapy.
"Advantages of C.I.M.N include the selective killing of cancer cells, activating normal cells rather than damaging them, lesser side effects (drug-induced sufferings), no tolerance, and no accumulation potential in the body. It is also effective in preventing occurrence and recurrence of various diseases as well as its therapeutic effects.
Given the chronic shortage of iodine that is reported in countries other than Japan, iodine will be likely needed for various purposes including the prevention of occurrence and recurrence of diseases as well as standard medical treatment in future."
[1] Iodine: Iodine is conventionally used as a contrast agent for x-ray and CT scan, disinfectant, mouth wash, thyroid disease drug, and so on as a therapeutic agent with high bactericidal effect. [2] Colloidal conversion: A technology for reducing the molecular weight of a substance to a level easily absorbed by the body, and converting the size to a level usable by biological cells.
About JCI Pharmaceutical Co., Ltd.
JCI Pharmaceutical Co., Ltd is pharmaceutical venture company specialized in research & development and production of colloidal iodine formulations. JCI Pharmaceuticals is the first company in the world to obtain an approval from the US FDA for the formulation of iodine converted to the colloidal state to allow it to be absorbed into the living body at large dosages.
The company aims to obtain approvals from the FDA for a colloidal iodine injection, an intravenous fluid, and internal medicines for pets, and intends to expand the application fields of colloidal iodine for various purposes in future. It also plans to commercialize a beverage for people with iodine deficiency as a functional health food. For more informationa, please visit http://jci-p.com/.
Contact:
Public Relations DivisionJCI Pharmaceutical Co., Ltd.Info.jci-p@jci-p.com
Disclaimer:The content on this press release is provided as of this date without warranties or representations of any kind, either express or implied, including but not limited to warranties or representations with respect to the accuracy, reliability, completeness, fitness for a particular purpose, or non-infringement of third parties' rights of the content. The information in this press release is not a substitute for professional medical advice or treatment for specific medical conditions. JCI does not undertake any obligation to update any information contained in this press release.This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, JCI shares in any country.
Source: JCI Pharmaceutical Co., Ltd.
Copyright 2014 ACN Newswire. All rights reserved.
